StemInov
Private Company
Total funding raised: $2.5M
Overview
StemInov is advancing a novel cell therapy platform based on Wharton's Jelly Mesenchymal Stem Cells (WJ-MSCs) for severe inflammatory conditions, with an initial focus on septic shock and ARDS stemming from severe pneumonia. Its lead product, WhartSep, is designed as a scalable, off-the-shelf therapy with three complementary mechanisms of action: antibacterial effects, immunomodulation, and organ protection. The company is preparing for a Phase Ib/IIa clinical trial in ICU patients, leveraging strong preclinical data and a founding team with deep clinical and scientific expertise in intensive care and cell therapy.
Technology Platform
Off-the-shelf allogeneic cell therapy platform using Wharton's Jelly-derived Mesenchymal Stem Cells (WJ-MSCs) with a multi-modal mechanism of action: antibacterial effects, adaptive immunomodulation, and organ protection/tropism.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
The critical care inflammatory space is highly competitive with numerous biopharma companies developing anti-inflammatory biologics, immunomodulators, and supportive care therapies. While cell therapies are less common in this acute setting, StemInov must demonstrate superior or complementary efficacy to established and emerging standard-of-care treatments. Other MSC-based therapies are in development for inflammatory conditions, but source (Wharton's Jelly) and specific targeting of severe pneumonia may differentiate WhartSep.